ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Indianapolis, IN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma

Lymphoma trials near Indianapolis, IN, USA:

Study of LYL314 in Aggressive Large B-Cell Lymphoma

chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma....

Enrolling
Relapsed Non-Hodgkin Lymphoma
Large B-cell Lymphoma
Drug: Cyclophosphamide
Drug: Fludarabine

Phase 1, Phase 2

Lyell Immunopharma

Indianapolis, Indiana, United States of America and 22 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...

Active, not recruiting
Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab

Phase 2

Genmab
Genmab

Indianapolis, Indiana, United States and 71 other locations

on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back af...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Indianapolis, Indiana, United States and 162 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: vinblastine
Drug: brentuximab vedotin

Phase 3

Takeda
Takeda

Indianapolis, Indiana, United States and 214 other locations

Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy...

Active, not recruiting
Lymphoma, T-Cell, Peripheral
Drug: Ixazomib
Drug: Romidepsin

Phase 1, Phase 2

Ryan Wilcox

Indianapolis, Indiana, United States and 6 other locations

the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma...

Enrolling
Hodgkin Lymphoma
Drug: Ruxolitinib
Drug: Nivolumab

Phase 1, Phase 2

Veronika Bachanova

Indianapolis, Indiana, United States and 4 other locations

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this dise...

Active, not recruiting
Follicular Lymphoma (FL)
Drug: Lenalidomide
Drug: Rituximab

Phase 3

Genmab
Genmab

Indianapolis, Indiana, United States and 281 other locations

is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL).This study will be...

Active, not recruiting
Follicular Lymphoma (FL)
Drug: Odronextamab
Drug: Rituximab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Noblesville, Indiana, United States and 191 other locations

well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemeto...

Enrolling
Transformed Non-Hodgkin Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Other: Questionnaire Administration
Biological: Tafasitamab

Phase 2

SWOG Cancer Research Network
SWOG Cancer Research Network

Indianapolis, Indiana, United States and 103 other locations

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatm...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Indianapolis, Indiana, United States and 231 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems